TOP2A and prostate cancer: In preclinical prostate cancer mouse cell line models, the simultaneous elevation of Top2a and EZH2 results in hypersensitivity to combined treatment with etoposide, a Top2-targeting toxin, and inhibitors of EZH2 [149].